posted
Stem-cell rally as sector moves broadly higher
By Val Brickates Kennedy Jan 4, 2007 13:24:00 (ET)
BOSTON (MarketWatch) -- Drug stocks moved higher Thursday, while shares of companies whose business focuses on stem cells scored major gains as Democrats assumed control of Congress for the first time since 1995.
The DJ Wilshire Pharmaceutical Index climbed 1% to 2395.92, with the DJ Wilshire Biotechnology Index jumping 2% to 3194.50.
Shares of stem-cell companies rallied, a reflection of hopes that a newly Democratic Congress will make good on its promise to lift certain restrictions on the public funding of embryonic stem-cell research put into place earlier this decade by the Bush administration. Any legislation would likely face a veto from President Bush.
Shares of StemCells Inc. (STEM, Trade ) jumped 13% to $3, while Aastrom Biosciences (ASTM, Trade ) shot up 10% to $1.36. Advance Cell Technology (ACTC, Trade ) also saw its shares get a boost, moving up 9% at 60 cents.
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
Advanced Cell Technology Inc. 1201 Harbor Bay Parkway Alameda, CA 94501 United States - Map Phone: 510-748-4900 Fax: 510-748-4950 Web Site: http://www.advancedcell.com
DETAILS Index Membership: N/A Sector: Healthcare Industry: Biotechnology Full Time Employees: 37
BUSINESS SUMMARY Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human stem cell technology in the fields of regenerative medicine and stem cell therapy in the United States. The company offers RPE cells for the treatment of age-related disease of the eye, including macular degeneration; hemangioblast cells for the treatment of various blood and cardiac disorders; and dermal cells for the treatment of dermal damage, including burns, wound repair, and surgery. It also develops and commercializes products for use in treatment of an array of chronic degenerative diseases and in regenerative repair of acute disease, such as trauma, infarction, and burns. The company, formerly known as A.C.T. Holdings, Inc., was founded in 1994 and is headquartered in Alameda, California.
Key Statistics
COMPANY WEBSITES Home Page
Search Yahoo! for: More on Advanced Cell Technology Inc.
ADVERTISEMENT
View Financials
KEY EXECUTIVES Pay Exercised Mr. William M. Caldwell IV, 58 Chairman, Chief Exec. Officer, Member of Compensation Committee and Member of Nominating & Corp. Governance Committee $ 366.00K $ 0 Dr. Michael D. West Ph.D., 53 Pres, Chief Scientific Officer $ 336.00K $ 0 Mr. Jonathan F. Atzen , 41 Sr. VP, Sec. and Gen. Counsel $ 234.00K $ 0 Dr. Robert P. Lanza M.D., 50 VP of Medical and Scientific Devel. and VP of Medical and Scientific Devel. - Advanced Cell Technology $ 344.00K $ 0 Mr. Ivan Wolkind , 40 Principal Financial Officer, Chief Accounting Officer and VP of Fin. N/A N/A
Dollar amounts are as of 31-Dec-05 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): January 3, 2007
ADVANCED CELL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Delaware
000-50295
87-0656515
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification Number)
1201 Harbor Bay Parkway, Alameda, California 94502
(Address of principal executive offices, including zip code)
(510) 748-4900
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
The Company announced today that it is negotiating an amendment to the Company’s Amortizing Convertible Debentures and Common Stock Purchase Warrants issued under the Securities Purchase Agreement dated as of September 15, 2005 (“2005 Debenture Financing”) and of the Company’s Amortizing Convertible Debentures and Common Stock Purchase Warrants issued under the Securities Purchase Agreement dated as of August 30, 2006 (“2006 Debenture Financing”) between the Company and the holders of such instruments to amend certain terms of these transactions as described below (the “Amendments”). Management expects the Amendments to close within the next several days. Unanimous approval of the holders is required in order for the Amendments to take effect.
The Amendments are expected to have the basic terms described below. All terms are subject to receipt of approval from the remaining uncommitted holders, and may vary materially from those set forth below. No assurance is given that the Company will be able to close the Amendments described herein, or that if the Amendments are closed that the terms and conditions of the Amendments will not differ materially from those described herein.
2005 Debenture Financing Amendment . Subject to receipt of approval of the remaining uncommitted holders, the transaction documents associated with the 2005 Debenture Financing will be amended in the following material respects:
· The conversion price of the debentures will be reset to $0.90.
· The exercise price of the warrants will be reset to $0.95.
· The debentures will be amended to give the Company the right to pay mandatory monthly redemptions in registered shares (or shares of Common Stock eligible for immediate resale under Rule 144) or cash, in the Company’s discretion.
· The Registration Rights Agreement will be amended so as to limit the number of shares of Common Stock required to be registered to an amount not in excess of the limits imposed by the Securities and Exchange Commission’s application of Rule 415 to secondary, resale registration statements, provided that the Company shall register not less than 30% of the Company’s issued and outstanding Common Stock (less shares held by affiliates of the Company) every six months until the registration requirements of the Registration Rights Agreement are satisfied in their entirety, and provided further that the Company shall continue to exercise best efforts to satisfy the registration requirements of the original Registration Rights Agreement as promptly as possible.
· The definition of “Exempt Issuance” will be expanded to include certain additional recipients of options issued under the Company’s approved stock option plans.
2006 Debenture Financing Amendment . Subject to receipt of approval of the remaining uncommitted holders, the transaction documents associated with the 2006 Debenture Financing will be amended in the following respects:
· The commencement of monthly redemptions will be deferred until September 7, 2007.
· The Company will be authorized to withdraw its pending Registration Statement, subject to satisfaction of the provisions of the amended Registration Rights Agreement described immediately below.
· The Registration Rights Agreement will be amended as follows: (a) to require the filing of an initial Registration Statement by the later of the 10 th trading day following the effective date of the Amendment, or January 19, 2007; (b) the number of shares of Common Stock required to be registered is limited to an amount not in excess of the limits imposed by the Securities and Exchange Commission’s application of Rule 415 to secondary, resale registration statements, provided that the Company shall register not less than 30% of the Company’s issued and outstanding Common Stock (less shares held by affiliates of the Company) every six months until the registration requirements of the Registration Rights Agreement are satisfied in their entirety, and provided further that the and provided further that the Company shall continue to exercise best efforts to satisfy the registration requirements of the original Registration Rights Agreement as promptly as possible.
· The Company will covenant to limit cash expenditures to an amount not in excess of $1.3 million per calendar month, subject to certain specified exceptions.
· The definition of “Exempt Issuance” will be expanded to include certain additional recipients of options issued under the Company’s approved stock option plans.
The Company had 39,131,426 shares of Common Stock issued and outstanding as of December 28, 2006.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
ADVANCED CELL TECHNOLOGY, INC.
By:
/s/ William M. Caldwell, IV
William M. Caldwell, IV
Chief Executive Officer
Dated: January 3, 2007
3 ACTC:US Advanced Cell Technology Inc
Industry: Medical-Biomedical/Gene Add Security to your Watch List
01/04 13:39 OTC BB Currency: USD
Price 0.600 Change 0.050 % Change 9.091 Bid 0.590 Ask 0.600 Open 0.550 Volume 758,711 High 0.630 Low 0.550 52-Week High 2.32 (08/24/06) 52-Week Low 0.26 (08/21/06) 1-Yr Return -70.000%
EARNINGS
Earnings Past 12 Months -2.560 Quarter Est. EPS() N.A. Quarter Est. EPS() N.A. Year Est. EPS() N.A. Price/Earnings (Trailing) N.A. Relative P/E N.A. Earnings Growth Rate N.A. Estimated P/E N.A.
FUNDAMENTALS
Shares (Millions) 33.415 Market Cap (Millions) 20.049 Float (Millions) 26.389 Return on Equity N.A. Short Interest N.A. Last Dividend Reported N.A. Dividend Yield (Trailing 12mo.) N.A. Relative Dividend Yield N.A. Composite Indicator Trend Spotter TM Sell
Short Term Indicators 7 Day Average Directional Indicator Sell 10 - 8 Day Moving Average Hilo Channel Sell 20 Day Moving Average vs Price Sell 20 - 50 Day MACD Oscillator Sell 20 Day Bollinger Bands Hold
Short Term Indicators Average: 80% - Sell 20-Day Average Volume - 404570
Medium Term Indicators 40 Day Commodity Channel Index Sell 50 Day Moving Average vs Price Sell 20 - 100 Day MACD Oscillator Sell 50 Day Parabolic Time/Price Sell
Medium Term Indicators Average: 100% - Sell 50-Day Average Volume - 468484
Long Term Indicators 60 Day Commodity Channel Index Sell 100 Day Moving Average vs Price Sell 50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 33% - Sell 100-Day Average Volume - 1075131
Overall Average: 80% - Sell
Price Support Pivot Point Resistance
0.5500 0.5133 0.5583 0.6033
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Advanced Cell Technology's William Caldwell Interviewed By Bloomberg Television
Jan 5, 2007 08:44:23 (ET) PPS .72
ALAMEDA, Calif., Jan 05, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) William M. Caldwell, IV, Chief Executive Officer, was interviewed by Bloomberg Television yesterday to comment on the effect the new Congress will have on stem cell funding in its first "100 Hours." As part of an 8-point plan during this time period, Congress has promised to push legislation through that would increase government funding for stem cell research.
Mr. Caldwell spoke of his optimism: "Right now there are bills in front of Congress to expand the lines for stem cell research, but I'm hopeful that this Congress will be cognizant of the fact that this research needs funding. The most important segment of this funding needs to be the translation from the basic science into the development of therapies and products. This void needs to be addressed not only by the government but also by private industry, foundations and consumer groups."
Advanced Cell's commitment to driving therapies to the clinic was recently highlighted in the scientific journal Nature, in a study describing the use of retinal pigment epithelial (RPE) cells derived from the Company's embryonic stem cells, in which vision function was rescued in blind rats. The Company expects to file an investigational new drug application (IND) with the FDA this year for its RPE program. The company expects, further to file INDs for its hemangioblast cell lines for blood and cardiac disorder, and for its dermal cell lines for skin and wound repair, next year.
"We're encouraged with what's happened over the last couple years, not only in California but just recently nationwide with the changes in Congress," said Mr. Caldwell. "Funding stem cell research is a national issue, that should be funded by the National Institute of Health (NIH) and other branches of the government because they have the standards and the policies in place."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Drug stocks mixed, stem cell companies gain
By Val Brickates Kennedy Jan 5, 2007 10:37:00 (ET)
BOSTON (MarketWatch) -- Drug stocks were mixed in early action Friday while shares of companies focused on stem cell research rallied for a second day on hopes the newly-Democratic Congress will make good on its promise to increase federal funding for that area of research.
The DJ Wilshire Pharmaceutical Index eased 0.2% to 2392.45 and the DJ Wilshire Biotechnology Index was relatively flat at 3210.56 during a relatively placid morning for the sectors on Wall Street.
Stem cell researchers were up again for the second day, having been on a roll since the Democrats officially took control of Congress on Thursday.
The new Democratic leadership has pledged to reintroduce legislation early this year that would lift certain restrictions on the federal funding of embryonic stem cell research that were put in place by the Bush administration earlier this decade. President Bush has said he would veto the legislation, as he has in the past.
Aastrom Biosciences (ASTM, Trade ) shares hopped 4% to $1.45, while StemCells Inc. (STEM, Trade ) stock rose 6% to $3.29. Shares of Advanced Cell Technology (ACTC, Trade ) jumped 7% to 73 cents a share.
Set Alerts
Create your Personalized SmartAlerts here.
Quotes
To get interactive quotes within this page, download Flash now
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Well my '07 is sucking ass already. I jumped in at .93, but sold a few minutes later at .89 like a complete moron...I was even debating on buying more around .89-.92 but decided to sell because I thought (shows how dumb I am) it'll tank like everything else I play...What happens after the shake? Explodes to $1.16...
Congrates dude! Can't imagine how much you banked on this...
Posts: 3026 | From: Chicago | Registered: Oct 2005
| IP: Logged |
I watched it closely the rest of the afternoon because it just drove me crazy how pathetic my trade was. Nice close. I'm thinking it'll gap, but wtf do I know? lol
Posts: 3026 | From: Chicago | Registered: Oct 2005
| IP: Logged |
posted
Related Quotes Sym. Price Chg. ACTC Trade News 1.035 0 Advanced Cell Technology CEO Interviewed on CNBC's ''Power Lunch''
Jan 11, 2007 08:33:25 (ET)
ALAMEDA, Calif., Jan 11, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) William M. Caldwell, IV, Chief Executive Officer, was interviewed on CNBC Television's "Power Lunch" yesterday to comment on a recent discovery by scientists at Wake Forest University describing a method of deriving stem cells from human amniotic fluid and a bill Congress is expected to take up today to widen the scope of funding for embryonic stem cell research.
Mr. Caldwell commented, "The key for any successful company is focus and we are very driven towards taking therapies, specifically for retinal, blood and cardiac disease into the clinic and ultimately patients. We are excited for Wake Forest and Doctor Atala...(t)hose breakthroughs are exciting and we are going to see more breakthroughs. It's important to remember that the key master cell is the embryonic stem cell and that's the one we are focused on."
Mr. Caldwell continued, "The industry has been starved for many years for lack of capital and we began seeing activity back in 2004 with the voters of California. Now with Congress revisiting the veto that occurred last summer we are going to see a lot more activity in the sector, and we are very excited about it."
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
Short Term Indicators 7 Day Average Directional Indicator Buy 10 - 8 Day Moving Average Hilo Channel Buy 20 Day Moving Average vs Price Buy 20 - 50 Day MACD Oscillator Sell 20 Day Bollinger Bands Hold
Short Term Indicators Average: 40% - Buy 20-Day Average Volume - 1840095
Medium Term Indicators 40 Day Commodity Channel Index Buy 50 Day Moving Average vs Price Buy 20 - 100 Day MACD Oscillator Sell 50 Day Parabolic Time/Price Buy
Medium Term Indicators Average: 50% - Buy 50-Day Average Volume - 1017646
Long Term Indicators 60 Day Commodity Channel Index Buy 100 Day Moving Average vs Price Buy 50 - 100 Day MACD Oscillator Buy
Long Term Indicators Average: 100% - Buy 100-Day Average Volume - 1370950
Overall Average: 64% - Buy
Price Support Pivot Point Resistance
0.9290 0.8097 0.8997 0.9897
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Advanced Cell Technology Awarded Federal Grant from National Institutes of Health to Accelerate Embryonic Stem Cell Research
Jan 16, 2007 09:33:06 (ET)
ALAMEDA, Calif., Jan 16, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, has been awarded a research grant from the National Institutes of Health (NIH) in the amount of $204,439 in conjunction with a research project currently underway with one of its academic partners, The Burnham Institute of Medical Research (Burnham Institute).
"This grant is momentous in part because it reflects the changing political climate and the federal government's move toward considerably greater support for research into embryonic stem cell science," said William M. Caldwell, IV, Chairman and Chief Executive Officer of Advanced Cell. "Increases in federal funding can trigger very significant growth in our industry, and grants such as these help companies like Advanced Cell deliver stem cell-based therapies to the bedside."
The grant, titled, "Directed Differentiation of Embryonic Stem Cells using Phage Displayed Ligands," unites Advanced Cell's expertise in embryonic stem cell biology, phage display, phage targeting technology and gene discovery, with Burnham Institute's expertise in developmental biology, cardiac biology, and vascular biology, among others.
"In today's world, medical research is increasingly a collaborative enterprise," said Dr. Michael West, President and Chief Scientific Officer of Advanced Cell. "We are thankful to the NIH and NIDCR for their support and confidence, and we are pleased to be collaborating with the Burnham Institute on this important project."
The NIH grant is issued under a program to foster collaboration between business and academia, and is an important step forward for Advanced Cell proprietary science in the field of embryonic stem cell technology. The award was granted to the company by the National Institute for Dental and Craniofacial Research (NIDCR), a division of the NIH.
The NIH grant will further fund research by Advanced Cell and the Burnham Institute aimed at obtaining specialized cells of therapeutic interest from human embryonic stem cells using NIH-approved stem cell lines. The researchers are investigating the genetic mechanisms and the specific proteins believed to control how basic embryonic stem cells develop and differentiate into specific cells and complex tissues. Such understanding is central to fully harnessing and directing the regenerative powers of stem cells in medical applications, and to the creation and commercialization of stem cell therapies.
Advanced Cell and Burnham Institute researchers are hopeful that their work will have broad application in the stem cell field. "Currently there is a critical need to understand how embryonic stem cells differentiate when cultured in the laboratory and how we can direct the differentiation process to produce cells that are safe and suitable for therapy," said Dr. David Larocca, Associate Director at Advanced Cell and Principal Investigator of the research program.
Advanced Cell and Burnham Institute researchers are focused on cells to treat diseases of the heart, skin, and vascular system.
For example, additional research in collaboration with Burnham Institute is designed to help address the critical unmet medical need for improved skin grafts by identifying new ways to produce human skin equivalents using embryonic stem cells. There is also research being done to develop new treatments for damage to heart muscle. The scientists will seek to develop reagents and processes for purification of cells called "cardiomyocyte precursor cells," and use them to prepare and test cells for cardiac repair.
"There are considerable opportunities in the field of regenerative medicine to use embryonic stem cells to develop therapeutic products to treat diseases where healthy cells may be used to replace those lost to injury or disease," said Dr. Mark Mercola, Ph.D., professor in the Stem Cells and Regeneration at the Burnham Institute. "This grant will allow us to build on our collaboration with Advanced Cell to use phage display as a tool to discover novel molecules for directing stem cells to form useful cell types and tissues."
Advanced Cell and the Burnham Institute recently identified a family of cell-targeting peptides that bind early differentiating human embryonic cells. Researchers are using these cell-targeted peptides to track their developmental fate. This will allow them to identify the precursors of important specialized cells. Once identified by cell-targeting peptides the precursor cells will be isolated and expanded for preclinical and clinical testing.
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Related Quotes Sym. Price Chg. ACTC Trade News 0.99 0.03 Advanced Cell Technology Announces Investor Conference Call to Be Held Friday January 19 to Discuss Key Events and Progress in Stem Cell-Based Therapeutic Programs
Jan 17, 2007 06:30:22 (ET)
ALAMEDA, Calif., Jan 17, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, will host an investor conference call on Friday, January 19, at 12 noon Eastern, to discuss recent progress and events with respect to the Company's initiatives to develop stem cell-based therapies for a range of diseases and conditions.
During the conference call, William M. Caldwell, IV, Chairman and Chief Executive Officer of Advanced Cell, will provide an overview of Company activities and news, and will address investor questions. Topics he will cover include the Company's recently announced federal research grant from the National Institutes of Health.
Mr. Caldwell will also comment on the impact of the current political climate on the advancement of stem cell based science and technologies. Some states, including California and New Jersey, have enacted legislation to foster stem cell science. Additionally, the newly elected governor of New York State, Eliot Spitzer, recently advocated passage of a $2 billion 10-year bond initiative for research and development, at least half of which would be earmarked for stem cell research.
Interested investors within the United States can access the conference call by calling (800) 553-5275; when prompted tell the operator you would like to connect to the 'Advanced Cell Technology' conference call. International callers can dial (612) 332-1210. An online audio web simulcast of the call will also be accessible at http://www.trilogy-capital.com/tcp/advanced_cell .
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
SmallCap Sentinel: Government Stem Cell Funding Sends Signal to Market
Jan 18, 2007 06:42:45 (ET)
IRVINE, Calif., Jan 18, 2007 (*********wire via COMTEX) -- "For an extended period of time, stem cell equities have busily conducted research under the black cloud of funding limitations," stated SmallCap Sentinel analyst D.R. Clark. "Now, with the political landscape having changed so dramatically, stem cell equities are finding a more welcoming and perhaps brighter path."
"Case in point, Advanced Cell Technology, Inc. (ACTC, Trade ) was awarded a research grant from the National Institutes of Health (NIH) in the amount of $204,439 in conjunction with a research project currently underway with one of its academic partners," Clark noted. "I believe this exemplifies a dramatic change in the government's sentiment toward stem cell research while simultaneously enhancing confidence for Advanced Cell's business plan."
"These types of funding events don't happen for every company that applies," Clark added. "This is a defining moment for Advanced Cell Technology."
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.
An informational report titled "Looking at the Political Impact on Stem Cell Research" has been made available free of charge via financial courier StockUpTicks.com at www.SmallCapSentinel.com . The report addresses Advanced Cell Technology, Inc. (ACTC, Trade ), StemCells Inc. (STEM, Trade ), Aastrom Biosciences Inc. (ASTM, Trade ), and Geron Corp. (GERN, Trade ).
To have your company featured in StockUpTicks or SmallCap Sentinel please contact the editors using the information below.
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
Information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities, but is rather a paid advertisement provided for information purposes only and shouldn't be used as basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Advanced Cell Technology, Inc. for preparation and distribution of this report and other advertising services. An editor of SmallCap Sentinel currently holds a position in STEM. This constitutes a conflict of interest as to MP's ability to remain objective in communication regarding the subject companies.
posted
WebAlert: Advanced Cell Technology Conference Call to Start Today at 12 Noon ET
Jan 19, 2007 06:30:10 (ET)
ALAMEDA, Calif., Jan 19, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ), applying proprietary human embryonic stem (ES) cell technology to the emerging field of regenerative medicine, will host a live investor conference call with a simultaneous webcast, today at 12 noon Eastern, to update investors on recent news and events, as well as progress with respect to the Company's initiatives to develop stem cell-based therapies for a range of diseases and conditions.
During the conference call, William M. Caldwell, IV, Chairman and Chief Executive Officer of Advanced Cell Technology, will provide an overview of Company activities and news, will address investor questions and comment on the impact of the current political climate on the advancement of embryonic stem cell science and development. Mr. Caldwell will also discuss the Company's recently announced federal research grant from the National Institutes of Health.
WHO: Advanced Cell Technology
WHAT: Investor Conference Call
WHEN: Today, January 19, 2007, at 12 noon Eastern
HOW: Callers within the United States may dial (800) 553-5275. When prompted, tell the operator that you would like to connect to the Advanced Cell conference call. International callers can dial (612) 332-1210.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California, and Worcester, Massachusetts.
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 Media: Bill Douglass, 212-825-3210 or Financial Communications Trilogy Capital Partners Paul Karon, 800-592-6067 paul*trilogy-capital.com
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Wink]](wink.gif)
![[Big Grin]](biggrin.gif)
